GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Treace Medical Concepts Inc (NAS:TMCI) » Definitions » Intrinsic Value: Projected FCF

Treace Medical Concepts (Treace Medical Concepts) Intrinsic Value: Projected FCF : $0.00 (As of Jun. 10, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Treace Medical Concepts Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-10), Treace Medical Concepts's Intrinsic Value: Projected FCF is $0.00. The stock price of Treace Medical Concepts is $5.91. Therefore, Treace Medical Concepts's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Treace Medical Concepts's Intrinsic Value: Projected FCF or its related term are showing as below:

TMCI's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.65
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Treace Medical Concepts Intrinsic Value: Projected FCF Historical Data

The historical data trend for Treace Medical Concepts's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Treace Medical Concepts Intrinsic Value: Projected FCF Chart

Treace Medical Concepts Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
- - - - -

Treace Medical Concepts Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Treace Medical Concepts's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, Treace Medical Concepts's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Treace Medical Concepts's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Treace Medical Concepts's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Treace Medical Concepts's Price-to-Projected-FCF falls into.



Treace Medical Concepts Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Treace Medical Concepts  (NAS:TMCI) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Treace Medical Concepts's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=5.91/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Treace Medical Concepts Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Treace Medical Concepts's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Treace Medical Concepts (Treace Medical Concepts) Business Description

Traded in Other Exchanges
N/A
Address
100 Palmetto Park Place, Ponte Vedra, FL, USA, 32081
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.
Executives
F Barry Bays director
Betsy Hanna director C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE RD #150, PONTE VEDRA BEACH FL 32081
Deepti Jain director 3701 WAYZATA BLVD, MINNEAPOLIS MN 55416
Sean F. Scanlan officer: See Remarks C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
James T Treace director 117 BRISTOL PLACE, PONTE VEDRA BEACH FL 32082
Richard W Mott director 1221 CROSSMAN AVENUE, SUNNYVALE CA 94089
Thomas E Timbie director
Daniel E. Owens officer: Chief HR Officer C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
Scot Michael Elder officer: *See "Remarks" C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
Mark Hair officer: Chief Financial Officer C/O RESTORATION ROBOTICS, INC., 128 BAYTECH DRIVE, SAN JOSE CA 95134
Aaron Berutti officer: Sr. VP, Sales C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
John T. Treace director, 10 percent owner, officer: Chief Executive Officer C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
Lance A Berry director 5677 AIRLINE ROAD, ARLINGTON TN 38002
Jane E Kiernan director 525 W ROSCOE, CHICAGO IL 60657
John R Treace director 5677 AIRLINE RD, ARLINGTON VA 38002

Treace Medical Concepts (Treace Medical Concepts) Headlines

From GuruFocus

Treace to Report First Quarter 2023 Financial Results on May 8, 2023

By sperokesalga sperokesalga 04-20-2023